Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Thrombopoietin receptor agonist ==Preliminary data== <span style="background:#00CD00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; ...") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Thrombopoietin receptor agonist | Thrombopoietin receptor agonist | ||
| + | |||
| + | =[[Autoimmune thrombocytopenic purpura (ITP)]]= | ||
==Preliminary data== | ==Preliminary data== | ||
| Line 14: | Line 16: | ||
YM477, AKR 501 | YM477, AKR 501 | ||
| − | [[Category: | + | [[Category:Drug index]] |
| − | |||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
[[Category:Immune thrombocytopenic purpura (ITP) medications]] | [[Category:Immune thrombocytopenic purpura (ITP) medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 03:43, 12 November 2014
Mechanism of action
Thrombopoietin receptor agonist
Autoimmune thrombocytopenic purpura (ITP)
Preliminary data
Randomized Phase II, >20 per arm
- Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed
Also known as
YM477, AKR 501